REVELATION BIOSCIENCES, INC.

Revelation Biosciences, Inc. (Nasdaq: REVB) is a clinical-stage biopharmaceutical company focused on developing novel immunology-based therapeutics. The company filed a Form 10-Q with the U.S. Securities and Exchange Commission on October 29, 2021, under accession number 0001213900-21-055498, providing a quarterly update on its financial position and pipeline progress. Operating within the life sciences and biotechnology sector, Revelation Biosciences has pursued programs targeting immune system pathways with its clinical-stage assets. The October 2021 quarterly filing reflects the company's ongoing reporting obligations as a publicly traded entity during an active phase of corporate and clinical development. Sign up at SpacDesk to access the full filing record, deal history, and comprehensive data coverage across the SPAC-era biotech landscape.